Passing the baton: The HIF switch

Trends in Biochemical Sciences

Volumn 37, Issue 9, 2012, Pages 364-372

  Koh, Mei Yee ^a   Powis, Garth ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Cancer; Development; Hypoxia; Hypoxia inducible factor; Stem cells

Indexed keywords

AGGRECAN; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN 3; ANGIOPOIETIN 4; COLLAGEN TYPE 2; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; MATRIX METALLOPROTEINASE; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RECEPTOR FOR ACTIVATED C KINASE 1; SIRTUIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; BONE DEVELOPMENT; CANCER INVASION; CANCER PROGNOSIS; CANCER STEM CELL; GENE ACTIVATION; GENE TARGETING; HUMAN; HYDROXYLATION; HYPOXEMIA; METASTASIS POTENTIAL; OXYGEN SUPPLY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; HUMANS; OXYGEN; STEM CELLS; TRANSCRIPTIONAL ACTIVATION;

EID: 84865429409     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2012.06.004     Document Type: Review

References (82)

1. Carreau A., et al. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J. Cell. Mol. Med. 2011, 15:1239-1253.
2. Pouyssegur J., et al. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
3. Wang G.L., et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:5510-5514.
4. Makino Y., et al. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J. Biol. Chem. 2002, 277:32405-32408.
5. Holmquist-Mengelbier L., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006, 10:413-423.
6. Koh M.Y., et al. The hypoxia-associated factor switches cells from HIF-1{alpha}- to HIF-2{alpha}-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res. 2011, 71:4015-4027.
7. Jaakkola P., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
8. Ohh M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2000, 2:423-427.
9. Maxwell P.H., et al. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 2001, 11:293-299.
10. Mahon P.C., et al. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15:2675-2686.
11. Koivunen P., et al. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 2004, 279:9899-9904.
12. Liu Y.V., Semenza G.L. RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle 2007, 6:656-659.
13. Ravi R., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000, 14:34-44.
14. Koh M.Y., et al. Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Mol. Cell. Biol. 2008, 28:7081-7095.
15. Luo W., et al. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but not HIF-2alpha. J. Biol. Chem. 2010, 285:3651-3663.
16. Bento C.F., et al. The chaperone-dependent ubiquitin ligase CHIP targets HIF-1alpha for degradation in the presence of methylglyoxal. PLoS ONE 2010, 5:e15062.
17. Tian H., et al. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997, 11:72-82.
18. Wiesener M.S., et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 2003, 17:271-273.
19. Raval R.R., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 2005, 25:5675-5686.
20. Mole D.R., et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 2009, 284:16767-16775.
21. Kapitsinou P.P., et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 2010, 116:3039-3048.
22. Warnecke C., et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 2004, 18:1462-1464.
23. Scortegagna M., et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005, 105:3133-3140.
24. Keith B., et al. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
25. Fujiwara S., et al. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int. J. Oncol. 2007, 30:793-802.
26. Appelhoff R.J., et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 2004, 279:38458-38465.
27. Uchida T., et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J. Biol. Chem. 2004, 279:14871-14878.
28. Sanchez M., et al. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat. Struct. Mol. Biol. 2007, 14:420-426.
29. Hu C.J., et al. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol. Biol. Cell 2007, 18:4528-4542.
30. Pringle K.G., et al. Beyond oxygen: complex regulation and activity of hypoxia inducible factors in pregnancy. Hum. Reprod. Update 2010, 16:415-431.
31. Flamme I., et al. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell Physiol. 1997, 173:206-210.
32. Augustin H.G., et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165-177.
33. Adams R.H., Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 2007, 8:464-478.
34. Fong G.H., et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
35. Oladipupo S., et al. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:13264-13269.
36. Oda N., et al. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J. Cell Physiol. 1999, 178:121-132.
37. Aprelikova O., et al. Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res. 2006, 66:5641-5647.
38. Takeda N., et al. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1. Circ. Res. 2004, 95:146-153.
39. Elvert G., et al. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J. Biol. Chem. 2003, 278:7520-7530.
40. Le Bras A., et al. HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 2007, 26:7480-7489.
41. Iyer N.V., et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12:149-162.
42. Kotch L.E., et al. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev. Biol. 1999, 209:254-267.
43. Ryan H.E., et al. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998, 17:3005-3015.
44. Yoon D., et al. Hypoxia-inducible Factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J. Biol. Chem. 2006, 281:25703-25711.
45. Peng J., et al. The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8386-8391.
46. Tian H., et al. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 1998, 12:3320-3324.
47. Compernolle V., et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 2002, 8:702-710.
48. Scortegagna M., et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat. Genet. 2003, 35:331-340.
49. Tang N., et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6:485-495.
50. Skuli N., et al. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 2009, 114:469-477.
51. Kronenberg H.M. Developmental regulation of the growth plate. Nature 2003, 423:332-336.
52. Rankin E.B., et al. A central role for hypoxic signaling in cartilage, bone, and hematopoiesis. Curr. Osteoporos. Rep. 2011, 9:46-52.
53. Saito T., et al. Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. Nat. Med. 2010, 16:678-686.
54. Duval E., et al. Hypoxia-inducible factor 1alpha inhibits the fibroblast-like markers type I and type III collagen during hypoxia-induced chondrocyte redifferentiation: hypoxia not only induces type II collagen and aggrecan, but it also inhibits type I and type III collagen in the hypoxia-inducible factor 1alpha-dependent redifferentiation of chondrocytes. Arthritis Rheum. 2009, 60:3038-3048.
55. Bohensky J., et al. HIF-1 regulation of chondrocyte apoptosis: induction of the autophagic pathway. Autophagy 2007, 3:207-214.
56. Bohensky J., et al. Regulation of autophagy in human and murine cartilage: hypoxia-inducible factor 2 suppresses chondrocyte autophagy. Arthritis Rheum. 2009, 60:1406-1415.
57. Yang S., et al. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat. Med. 2010, 16:687-693.
58. Shomento S.H., et al. Hypoxia-inducible factors 1alpha and 2alpha exert both distinct and overlapping functions in long bone development. J. Cell Biochem. 2010, 109:196-204.
59. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-239.
60. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11:393-410.
61. Zhong H., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
62. Franovic A., et al. Human cancers converge at the HIF-2alpha oncogenic axis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21306-21311.
63. Mandriota S.J., et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468.
64. Shen C., et al. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov. 2011, 1:222-235.
65. Gordan J.D., et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14:435-446.
66. Wagers A.J., Weissman I.L. Plasticity of adult stem cells. Cell 2004, 116:639-648.
67. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
68. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 2008, 26:2839-2845.
69. Scadden D.T. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
70. Jögi A., et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7021-7026.
71. Mukherjee T., et al. Interaction between Notch and Hif-α in development and survival of Drosophila blood cells. Science 2011, 332:1210-1213.
72. Hu C.J., et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 2003, 23:9361-9374.
73. Li Z., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
74. Soeda A., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1[alpha]. Oncogene 2009, 28:3949-3959.
75. Pietras A., et al. The HIF-2alpha-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. Curr. Top. Microbiol. Immunol. 2010, 345:1-20.
76. Wang Y., et al. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8:399-411.
77. Tavazoie M., et al. A specialized vascular niche for adult neural stem cells. Cell Stem Cell 2008, 3:279-288.
78. Gilbertson R.J., Rich J.N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 2007, 7:733-736.
79. Pietras A., et al. HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16805-16810.
80. Lim J.-H., et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1α. Mol. Cell 2010, 38:864-878.
81. Chen R., et al. Hypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent manner. J. Biol. Chem. 2011, 286:13869-13878.
82. Laemmle A., et al. Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1alpha protein under hypoxic conditions. PLoS ONE 2012, 7:e33433.